These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 37488535)
1. The expression profiles of signature genes from CD103 Xia ZA; Lu C; Pan C; Li J; Li J; Mao Y; Sun L; He J BMC Med; 2023 Jul; 21(1):268. PubMed ID: 37488535 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. Truntzer C; Isambert N; Arnould L; Ladoire S; Ghiringhelli F Eur J Cancer; 2019 Oct; 120():97-106. PubMed ID: 31499385 [TBL] [Abstract][Full Text] [Related]
3. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825 [TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978 [TBL] [Abstract][Full Text] [Related]
5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
6. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842 [TBL] [Abstract][Full Text] [Related]
7. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905 [TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Wang K; Xu J; Zhang T; Xue D Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588 [TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962 [TBL] [Abstract][Full Text] [Related]
10. Functional Heterogeneity of CD4 Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P Front Immunol; 2018; 9():2654. PubMed ID: 30505306 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Chung YR; Kim HJ; Jang MH; Park SY Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer. Park MH; Kwon SY; Choi JE; Gong G; Bae YK Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690 [TBL] [Abstract][Full Text] [Related]
13. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis. Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S Front Immunol; 2023; 14():1238312. PubMed ID: 37908350 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M Front Immunol; 2022; 13():973974. PubMed ID: 36211333 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers of tumor-reactive CD4 Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331 [TBL] [Abstract][Full Text] [Related]
16. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer. Qiu P; Guo Q; Yao Q; Chen J; Lin J Front Immunol; 2021; 12():736030. PubMed ID: 34659224 [TBL] [Abstract][Full Text] [Related]
18. Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles. Jiang J; Pan W; Xu Y; Ni C; Xue D; Chen Z; Chen W; Huang J J Cancer; 2020; 11(6):1568-1583. PubMed ID: 32047563 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B Front Immunol; 2022; 13():931906. PubMed ID: 35958598 [TBL] [Abstract][Full Text] [Related]
20. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Seo AN; Lee HJ; Kim EJ; Kim HJ; Jang MH; Lee HE; Kim YJ; Kim JH; Park SY Br J Cancer; 2013 Nov; 109(10):2705-13. PubMed ID: 24129232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]